Molecular determinants of epistasis in HIV-1 protease: Elucidating the interdependence of L89V and L90M mutations in resistance

Protease inhibitors have the highest potency among antiviral therapies against HIV-1 infections, yet the virus can evolve resistance. Darunavir (DRV), currently the most potent FDA approved protease inhibitor, retains potency against single site mutations. However, complex combinations of mutations...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Biochemistry
Auteurs principaux: Henes, Mina, Kosovrasti, Klajdi, Lockbaum, Gordon J., Leidner, Florian, Nachum, Gily S., Nalivaika, Ellen A., Bolon, Daniel N.A., Yilmaz, Nese Kurt, Schiffer, Celia A., Whitfield, Troy W.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941756/
https://ncbi.nlm.nih.gov/pubmed/31386353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.biochem.9b00446
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires